Navigation Links
Limiting Eligibility for Medical Studies Can Omit Women,,African-Americans, Stanford Study Finds

er that the majority of depressed people are women."

Based on the paper's findings, Humphreys said he would encourage researchers to carefully examine the rationale of a study's eligibility criteria. "Researchers need to say to themselves, 'I'm only going to make the decision to exclude certain patients if there is a good reason for it,'" he said.

Humphreys and his colleagues are also urging designers of alcohol treatment studies to stop excluding patients with drug problems. "Eighty percent of patients with alcohol problems use some sort of drug, so there is a strong case for including these patients in studies," he said.

This study was funded by the National Institute on Alcohol Abuse and Alcoholism, and the Department of Veterans Affairs Health Services Research and Development Service. Humphreys' co-authors include the VA's Kenneth Weingardt, PhD, and Alex Harris, PhD.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions -- Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital at Stanford. For more information, please visit the Web site of the medical center's Office of Communication & Public Affairs at http://mednews.stanford.edu.

Contact

Print Media
Michelle Brandt, 650-723-0272
mbrandt@stanford.edu
or
Margarita Gallardo, 650-723-7897
mjgallardo@stanford.edu
or
Broadcast Media
M.A. Malone, 650-723-6912
mamalone@stanford.edu


'"/>




Page: 1 2 3

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
5. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
6. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
7. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
8. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
9. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
10. Introgen and Clinical Collaborators to Report New Results with Advanced-Stage Cancer Therapies at Upcoming Medical Meetings
11. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings

Post Your Comments:
(Date:12/3/2009)... YORK, Dec. 3 Alzheimer,s disease ...person can receive. This irreversible, progressive... skills and eventually even the ability to carry o...mentia among older people, AD affects as many as 2...the National Institute on Aging. ,, (Logo: h...
(Date:12/3/2009)...ON, Texas, Dec. 3 ULURU... Medical-Surgical, Inc., one of the major pharmace...oved ULURU Inc. to be one of its suppliers and has...TM). McKesson Medical-Surgical delivers a comprehe...al equipment and health care technology-related se...
(Date:12/3/2009)...ISCATAWAY, N.J., Dec. 3 ...S), the recognized leader in advanced injection te...to a joint venture with China National Medicines C...manwell Pharmaceutical Co. Ltd., both incorporated... develop orthopedic and epidural drug delivery ins...
Breaking Medicine Technology:Alzheimer's Research May Lead to Preventing the Debilitating Disease 2Alzheimer's Research May Lead to Preventing the Debilitating Disease 3ULURU Inc. Obtains Status of Approved Supplier With McKesson. 2Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 2Milestone Scientific to Establish Joint Venture to Develop Medical Drug Delivery Instruments 3Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 1Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 2Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 3Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 4Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 5Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 6Dow AgroSciences Monsanto Complete U S and Canadian Regulatory Authorizations for SmartStax Corn 3B Plans Set to Launch Seed Platform on 3 Million 13098 7Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses 13096 1Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses 13096 2Double Helix Strengthens its Strategic Pricing and Reimbursement Practice with Hire of Caryn Zieses 13096 3Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 1Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 2Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 3Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 4Idenix Pharmaceuticals Successfully Completes Proof of Concept Study of IDX184 for the Treatment of Hepatitis C Virus 28HCV 29 4752 5
(Date:12/3/2009)... , PASADENA, Calif., Dec. 3 F...inesses, the risk of disability remains one of the...al financial well being, but also their business,s...clines have taken their toll, owners of small busi...financial safety net with enhanced disability cove...
(Date:12/3/2009)...Hughes Medical Institute (HHMI) researchers have i...evelopment of many forms of medulloblastoma, the m...r., HHMI investigator Huda Y. Zoghbi and colleag...oblastoma from developing in mice by shutting down...ain cells. The team,s findings, reported in the De...
(Date:12/3/2009)... , Massachusetts Does Little to Make Lung Ca...GTON, Dec. 3 Today, L...its 3rd Annual Report Card on Lung Cancer . The ...g made against this lethal disease in the state of...r Alliance (LCA), the only national organization d...
(Date:12/3/2009)... , More than 1,500 Jobs Listed through APHA...Dec. 3 Today,s White Ho...ployment across many professions, including public... the need and connect job seekers to more than 1,5...areerMart at http://www.apha.org/about/careers/ ...
(Date:12/3/2009)...K (December 3, 2009) -- When the heart is stopped ... their brain is often permanently damaged. Therape...,s body temperature is lowered and maintained seve... been shown to mitigate these harmful effects and ...large-scale multicenter study of its kind, physici...
Breaking Medicine News(10 mins):Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4Health News:Researchers identify gene that spurs deadly brain cancer 2Health News:Researchers identify gene that spurs deadly brain cancer 3Health News:Lung Cancer Alliance-Massachusetts Releases 3rd Annual State-Specific Report Card on Lung Cancer 2Health News:Public Health Jobs Site Available to Help Meet Growing Demand 2Health News:Cooling may benefit children after cardiac arrest 2
...us system cells that support brain function, study...ews) -- The impact of amyloid plaques in the brain...omplex than believed, U.S. researchers report. , I...d that amyloid plaques may also increase the activ...
...r of Americans traveling abroad for healthcare is ...mer trend as the recession worsens and more Americ... medical bills at U.S. hospitals. , , According t...on by 2017. The $16 billion in cross border revenu...
...ch suggests taking proper care of your teeth and g... Here,s more on the emerging association between o...eport from Colgate-Palmolive at: http://inr.media...unrestricted use at http://www.mediaseed.tv . , ...
...s years teaching and mentoring young orthopaedic s...ucation in underserved communities and helping col...he long list of achievements that led to Blair C. ...esented to Dr. Filler at the American Academy of O...
...it was filed today by Latherow Law,Office on behal...oisoning,after eating at a Blueberry Hill Restaura... child was hospitalized for three days as a result... also,contracted salmonella poisoning after eating...
...S Caremark Corporation (NYSE: CVS ) today announ...Chief Financial Officer and Chief Administrative O... at the Raymond James Institutional Investors Conf...6/NE75914LOGO ) , , An audio webcast of the pres...
Other Medicine News:Health News:Alzheimer's Plaques More Complex Than Thought 2Health News:Americans Will Soon Have Medical Butlers to Assist in Medical Tourism Research 2Health News:Blair C. Filler, M.D. Receives 2009 Tipton Award for Outstanding Orthopaedic Leadership 2Health News:Blair C. Filler, M.D. Receives 2009 Tipton Award for Outstanding Orthopaedic Leadership 3Health News:CVS Caremark Corporation to Present at the Raymond James Institutional Investors Conference on March 10th 2
...ng (ACB®) Test is a clinical chemistry assay t...y measuring the cobalt binding capacity of albumin...e early 1990s, IMA is produced when circulating al... heart. During ischemia, the N-terminus of albumin...
...ng (ACB®) Test is a clinical chemistry assay t...y measuring the cobalt binding capacity of albumin...e early 1990s, IMA is produced when circulating al... heart. During ischemia, the N-terminus of albumin...
...ng (ACB®) Test is a clinical chemistry assay t...y measuring the cobalt binding capacity of albumin...e early 1990s, IMA is produced when circulating al... heart. During ischemia, the N-terminus of albumin...
...its that quantitatively measure two important card.... An elevated serum or plasma homocysteine level i...risk factor for cardiovascular disease. And numero...levated levels of Lp(a) with increased risk of cor...
Medicine Products: